DoH Policies screened during the period: 1 July 2024 – 30 September 2024
Date published:
Last updated:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- NICE Technology Appraisal TA979 - Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (PDF 513KB)
- NICE Technology Appraisal TA981 - Voxelotor for treating haemolytic anaemia caused by sickle cell disease (PDF 513KB)
- NICE Technology Appraisal TA983 - Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (PDF 515KB)
- NICE Technology Appraisal TA984 - Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (review of TA696) (PDF 514KB)
- NICE Clinical Guideline NG240 - Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (updates and replaces CG102) (PDF 565KB)
- NICE Technology Appraisal TA985 - Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (partial review of TA688). (PDF 511KB)
- NICE Technology Appraisal TA986 - Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (PDF 514KB)
- NICE Technology Appraisal TA988 - Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (PDF 517KB)
- NICE Technology Appraisal TA990 - Tenecteplase for treating acute ischaemic stroke (PDF 512KB)
- NICE Technology Appraisal TA992 - Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (PDF 514KB)
- NICE Technology Appraisal TA991 - Abaloparatide for treating osteoporosis after menopause (PDF 512KB)
- NICE Technology Appraisal TA993 - Burosumab for treating X-linked hypophosphataemia in adults (PDF 621KB)
- NICE Technology Appraisal TA995 - Relugolix for treating hormone-sensitive prostate cancer (PDF 512KB)
- NICE Technology Appraisal TA996 - Linzagolix for treating moderate to severe symptoms of uterine fibroids (PDF 557KB)
- NICE Technology Appraisal TA998 - Risankizumab for treating moderately to severely active ulcerative colitis (PDF 557KB)
- NICE Technology Appraisal TA997 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (partial review of TA737)
- NICE Technology Appraisal TA999 - Vibegron for treating symptoms of overactive bladder syndrome (PDF 512KB)
- NICE Technology Appraisal TA1000 - Iptacopan for treating paroxysmal nocturnal haemoglobinuria (PDF 512KB)
- The Period Products (Free Provision) Act (Northern Ireland) 2022 (PDF 522KB)
- Introduction of Section 62 Emergency Prohibition Order under the Medicines Act 1968 to prohibit the inappropriate use of gender dysphoria medicines in children (PDF 449KB)
- Selection process for local Government representatives for shadow Area Integrated Partnership Boards (AIPBs). (PDF 349KB)
- NICE Technology Appraisal TA1001 - Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (PDF 623KB)
- NICE Technology Appraisal TA1002 - Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (PPF 516KB)